液基细胞学和HPV-DNA检测在宫颈疾病筛查中的应用

Application value of TCT combined with HPV-DNA in cervical diseases screening

目的探讨TCT联合HPV-DNA在筛查宫颈病变中的应用价值。方法对2008年1月至2009年12月就诊于郑州市第三人民医院妇科门诊1060例患者行宫颈液基细胞学(TCT)和宫颈HPV-DNA的筛查,采取TBS报告方式,对ASC-US以上的患者和(或)HPV-DNA检测阳性的患者行宫颈活检。结果 1060例TCT检查的患者中,ASC-US以上者235例,HPV阳性者282例,其阳性检出率分别为22.17%、26.60%;TCT和HPV-DNA均阳性者186例,占15.75%,病理结果示宫颈浸润性鳞癌6例,CINⅠ是92例,CINⅡ-Ⅲ为65例,分别为0.57%,8.68%,6.13%。结论 TCT联合HPV-DNA能提高宫颈病变的检出率,可作为宫颈病变的筛查诊断方法。

Objective To investigate application value of TCT combined with HPV-DNA in the cervical diseases screening.Methods Totally 1060 outpatients in Zhengzhou the third people’s hospital were screened by TCT and HPV-DNA.The patients with ASC-US and worse were cervical biopsy.Results There are 235 patients above ASC-US and 282 patients are HPV positive in 1060 outpatients.The positive rate is 22.17% and 26.60% respectively.There are 186 patients with both positive of TCT and HPV-DNA,which take in 15.75%.Phathological results show that there are 6 cervical invasive squamous cancer patients,92 CINⅠ patients,65 CINⅡ~Ⅲ patients,which take in 0.57%,8.68% and 6.13% respectively.Conclusions TCT combined with HPV-DNA can improve the positive rate of cervical diseases screening,which can be a promising screening method for cervical dysplasia.